Vital Biopharmaceutical Insights and Analytics

for Experts from Experts

Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.

Learn More

Featured Report
Therapies for NSCLC: How High are the Barriers to Displacing Avastin in Europe?

The cost of Roche/Chugai’s Avastin, followed by concerns about its efficacy and side-effect profile, are cited most frequently by surveyed oncologists as the factors preventing their use of Avastin for non-small-cell lung cancer treatment in Germany, France, Italy, Spain and the United Kingdom...Learn More

Featured Webinar
Despite Physicians' Conservative Attitude Towards Biosimilars, TNF-Alpha Inhibitors Stand to Lose $22 Billion in Sales

On Demand...Learn More

View Webinar schedule and archive

Search Reports

TOP TEN REPORTS

See which reports have been searched on the most.

Go

In the Spotlight

Free White Paper


Click here to download our free white paper and learn how brand perception research can help marketers of emerging agents identify relevant drivers of brand choice, uncover key physician segments to target as they launch and understand the competitive market landscape.

Latest Press Releases [ view all ]

  • December 22, 2009

    Spiriva Has Closed the Gap in Patient Share Between Itself and Advair For the Treatment of COPD...Read More

  • December 17, 2009

    Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer...Read More

  • December 17, 2009

    Over 70 Percent of Physicians Say There is a High Need for More Diabetes Drugs With Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors...Read More

Recent Reports [ view all ]

  • Atrial Fibrillation

    Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in clinical practice. The... Read More

  • Brand Perceptions in Noninsulin Antidiabetics

    In 2008, sales of noninsulin type 2 diabetes agents surpassed $7 billion in the United States with sales of Takeda’s... Read More

  • Emerging Pharmaceutical Blockbusters: 2010's Billion-Dollar Babies

    Drugs commanding more than $1 billion in annual sales are the blockbusters and mega-blockbusters that biopharmaceutical... Read More

 © 2009 Decision Resources, Inc. All rights reserved.